Wang Jing, Qiao Chunxia, Xiao He, Lin Zhou, Li Yan, Zhang Jiyan, Shen Beifen, Fu Tinghuan, Feng Jiannan
Department of Molecular Immunology, Beijing Institute of Basic Medical Sciences.
First Affiliated Hospital of PLA General Hospital, Beijing, People's Republic of China.
Drug Des Devel Ther. 2016 Dec 15;10:4091-4100. doi: 10.2147/DDDT.S118457. eCollection 2016.
According to the three-dimensional (3D) complex structure of (hIL-6⋅hIL-6R⋅gp 130) and the binding orientation of hIL-6, three compounds with high affinity to hIL-6R and bioactivity to block hIL-6 in vitro were screened theoretically from the chemical databases, including 3D-Available Chemicals Directory (ACD) and MDL Drug Data Report (MDDR), by means of the computer-guided virtual screening method. Using distance geometry, molecular modeling and molecular dynamics trajectory analysis methods, the binding mode and binding energy of the three compounds were evaluated theoretically. Enzyme-linked immunosorbent assay analysis demonstrated that all the three compounds could block IL-6 binding to IL-6R specifically. However, only compound 1 could effectively antagonize the function of hIL-6 and inhibit the proliferation of XG-7 cells in a dose-dependent manner, whereas it showed no cytotoxicity to SP2/0 or L929 cells. These data demonstrated that the compound 1 could be a promising candidate of hIL-6 antagonist.
根据(hIL-6⋅hIL-6R⋅gp130)的三维(3D)复杂结构以及hIL-6的结合取向,通过计算机辅助虚拟筛选方法,从化学数据库(包括3D可利用化学物质目录(ACD)和MDL药物数据报告(MDDR))中理论上筛选出三种对hIL-6R具有高亲和力且在体外具有阻断hIL-6生物活性的化合物。运用距离几何、分子建模和分子动力学轨迹分析方法,从理论上评估了这三种化合物的结合模式和结合能。酶联免疫吸附测定分析表明,所有这三种化合物都能特异性地阻断IL-6与IL-6R的结合。然而,只有化合物1能够有效拮抗hIL-6的功能,并以剂量依赖的方式抑制XG-7细胞的增殖,而对SP2/0或L929细胞无细胞毒性。这些数据表明化合物1可能是一种有前景的hIL-6拮抗剂候选物。